Madrigal Shatters Street Expectations With $62m In Q3 Rezdiffra Sales

 
• By Joseph Haas
  
Madrigal's Rezdiffra is off to a promising launch in NASH (Shutterstock)

More from Earnings

More from Therapy Areas